Braveheart Bio (NASDAQ:BRVE) Given Overweight Rating at Cantor Fitzgerald

Braveheart Bio (NASDAQ:BRVE)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $40.00 target price on the stock. Cantor Fitzgerald‘s target price suggests a potential upside of 97.34% from the company’s previous close.

Several other research firms have also recently commented on BRVE. The Goldman Sachs Group started coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 target price on the stock. Jefferies Financial Group started coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 target price on the stock. TD Cowen began coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating on the stock. Zacks Research raised shares of Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. Finally, Stifel Nicolaus began coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $45.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Braveheart Bio Price Performance

NASDAQ BRVE traded up $1.06 during trading hours on Tuesday, hitting $20.27. The company’s stock had a trading volume of 323,870 shares, compared to its average volume of 465,361. Braveheart Bio has a 52 week low of $17.86 and a 52 week high of $32.00. The stock has a market capitalization of $1.83 billion and a P/E ratio of -8.08. The company’s 50-day moving average price is $24.41.

Braveheart Bio (NASDAQ:BRVE) last posted its earnings results on Tuesday, September 8th. The company reported ($2.51) EPS for the quarter, missing the consensus estimate of ($0.25) by ($2.26). On average, research analysts anticipate that Braveheart Bio will post -1.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Erez Chimovits purchased 1,940,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the acquisition, the director owned 11,901,826 shares of the company’s stock, valued at $214,232,868. This trade represents a 19.47% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director David Lubner purchased 55,555 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $999,990.00. Following the acquisition, the director directly owned 55,555 shares in the company, valued at $999,990. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 8,751,942 shares of company stock worth $157,534,956 in the last three months.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.